<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">BCP</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7163384</article-id><article-id pub-id-type="pmcid-ver">PMC7163384.1</article-id><article-id pub-id-type="pmcaid">7163384</article-id><article-id pub-id-type="pmcaiid">7163384</article-id><article-id pub-id-type="pmid">31840271</article-id><article-id pub-id-type="doi">10.1111/bcp.14200</article-id><article-id pub-id-type="publisher-id">BCP14200</article-id><article-id pub-id-type="other">MP-00654-19.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation</article-title><alt-title alt-title-type="left-running-head">Kim et al.</alt-title></title-group><contrib-group><contrib id="bcp14200-cr-0001" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="BR">Bo Rim</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9464-0150</contrib-id><xref ref-type="aff" rid="bcp14200-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp14200-cr-0002" contrib-type="author"><name name-style="western"><surname>Oh</surname><given-names initials="J">Jaeseong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6275-8587</contrib-id><xref ref-type="aff" rid="bcp14200-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bcp14200-cr-0003" contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="KS">Kyung&#8208;Sang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0921-7225</contrib-id><xref ref-type="aff" rid="bcp14200-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bcp14200-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Ryu</surname><given-names initials="HG">Ho Geol</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8952-6049</contrib-id><xref ref-type="aff" rid="bcp14200-aff-0001">
<sup>1</sup>
</xref><address><email>hogeol@gmail.com</email></address></contrib></contrib-group><aff id="bcp14200-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Departments of Anesthesiology &amp; Pain Medicine, Seoul National University College of Medicine</named-content>
<institution>Seoul National University Hospital</institution>
<city>Seoul</city>
<country country="KR">South Korea</country>
</aff><aff id="bcp14200-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Clinical Pharmacology &amp; Therapeutics, Seoul National University College of Medicine</named-content>
<institution>Seoul National University Hospital</institution>
<city>Seoul</city>
<country country="KR">South Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ho Geol Ryu, Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine. Seoul National University Hospital, 101 Daehak&#8208;ro, Jongno&#8208;gu, Seoul, South Korea, 110&#8208;744.<break/>
Email: <email>hogeol@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2020</year></pub-date><volume>86</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">356134</issue-id><issue-id pub-id-type="doi">10.1111/bcp.v86.5</issue-id><fpage>923</fpage><lpage>932</lpage><history><date date-type="received"><day>20</day><month>8</month><year>2019</year></date><date date-type="rev-recd"><day>18</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-05-01 00:16:28.997"><day>01</day><month>05</month><year>2021</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2019 The British Pharmacological Society</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BCP-86-923.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BCP-86-923.pdf"/><abstract><sec id="bcp14200-sec-0001"><title>Aims</title><p>Antithrombin III (AT&#8208;III) concentrates have been used to prevent critical thrombosis in the immediate post&#8208;liver transplantation period without clear evidence regarding the optimal dose or administration scheme. The relationship between the AT&#8208;III dosage and the plasma activity levels during the period was evaluated in this study.</p></sec><sec id="bcp14200-sec-0002"><title>Methods</title><p>The plasma AT&#8208;III activity levels and clinical data obtained from patients who received liver transplantation from January 2017 to September 2018 were retrospectively analysed. A population pharmacokinetic (PK) model was developed using nonlinear mixed&#8208;effects method and externally validated thereafter. Several dosing scenarios were simulated to maintain the plasma AT&#8208;III activity level within the normal range using the developed PK model to search for an optimal AT&#8208;III dosing regimen.</p></sec><sec id="bcp14200-sec-0003"><title>Results</title><p>The plasma AT&#8208;III activity levels were best described by a single compartment model with first order elimination kinetics. The recovery of endogenous AT&#8208;III level during the postoperative days was modelled using an E<sub>max</sub> model. The typical values (95% confidence interval) of volume of distribution and clearance were 3.86 (3.40&#8211;4.32) L, and 0.129 (0.111&#8211;0.147) L h<sup>&#8722;1</sup>, respectively. Serum albumin and body weight had significant effect on clearance and were included in the model. External validation of the proposed model demonstrated adequate prediction performance. Furthermore, simulation of previously suggested or modified dosing scenarios showed successful maintenance of AT&#8208;III activity level within the normal range.</p></sec><sec id="bcp14200-sec-0004"><title>Conclusion</title><p>A population PK model of AT&#8208;III concentrate was developed using data from liver recipients. Dosing scenarios simulated in our study may help establish a practical guide for AT&#8208;III concentrate titration after liver transplantation.</p></sec></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="bcp14200-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="nlm-graphic-1" orientation="portrait" xlink:href="BCP-86-923-g006.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcp14200-kwd-0001">antithrombin III</kwd><kwd id="bcp14200-kwd-0002">dosage</kwd><kwd id="bcp14200-kwd-0003">liver transplantation</kwd><kwd id="bcp14200-kwd-0004">population pharmacokinetics</kwd></kwd-group><counts><fig-count count="6"/><table-count count="2"/><page-count count="10"/><word-count count="6052"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:17.04.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcp14200-cit-9001"><string-name name-style="western"><surname>Kim</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>K&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>HG</given-names></string-name>. <article-title>Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2020</year>;<volume>86</volume>:<fpage>923</fpage>&#8211;<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.14200</pub-id><pub-id pub-id-type="pmcid">PMC7163384</pub-id><pub-id pub-id-type="pmid">31840271</pub-id></mixed-citation>
</p><fn-group id="bcp14200-ntgp-0001"><fn id="bcp14200-note-0001"><p>Bo Rim Kim and Jaeseong Oh have equally contributed to this work and are co&#8208;first authors.</p></fn><fn id="bcp14200-note-0002"><p>The authors confirm that the Principal Investigator for this paper is Ho Geol Ryu and that he had direct clinical responsibility for the patients.</p></fn></fn-group></notes></front></article></pmc-articleset>